Terminal differentiation is a process whereby highly specialized cells commit irreversibly to a cellular fate and undergo growth arrest. Recent studies in cardiac muscle have identified two major families of proteins involved in cardiac terminal differentiation, pocket proteins (retinoblastoma gene product (Rb), p107, p130) and the transcriptional coactivators, p300/CBP. One explanation for the dependence of normal differentiation on pocket proteins, is the requirement of some tissue-specific transcription factors on the coexpression of Rb for transcriptional activity. This led us and others to hypothesize that Rb might be the key to terminal differentiation in cardiac myocytes. However, the mechanism underlying this dependence or the factors interacting with Rb are unknown. Therefore, to determine the factors interacting with Rb in cardiac muscle, we utilized the yeast two-hybrid system to identify cardiac Rb- binding proteins. One novel protein, designated p300- and Rb- binding Inhibitor of differentiation-1 (PRI-1) was the predominant Rb-binding clone. PRI-1 is preferentially expressed in cardiac and skeletal muscle in a developmentally regulated manner. Initial studies in skeletal muscle demonstrated that overexpression of PRI-1 inhibited muscle-specific transcription. Repression of skeletal muscle-restricted genes was mediated by a block to transactivation by MyoD, independent of G1 exit, and, surprisingly, was potentiated by a mutation that prevents PRI-1 binding to Rb. Inhibition of MyoD may be explained by PRI-1's ability, like adenoviral protein E1A, to bind p300, an essential MyoD coactivator. Thus, PRI-1 binds both Rb and p300, was inhibited by Rb in differentiated muscle, and was a novel repressor of MyoD function. Studies in cardiac muscle demonstrate that PRI-1 also inhibits cardiac-specific gene expression although the mechanism or potential targets of PRI-1's inhibitory effects are unknown. Thus PRI-1 represents one of the first endogenous, mammalian inhibitors of cardiac differentiation to be identified. This first RO1 proposes to further define the role of PRI-1 in cardiac myocyte differentiation and elucidate its biochemical properties.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL062448-03
Application #
6527592
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Program Officer
Pearson, Gail D
Project Start
2000-09-01
Project End
2004-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
3
Fiscal Year
2002
Total Cost
$229,500
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Schenke-Layland, Katja; Strem, Brian M; Jordan, Maria C et al. (2009) Adipose tissue-derived cells improve cardiac function following myocardial infarction. J Surg Res 153:217-23
Heydarkhan-Hagvall, Sepideh; Schenke-Layland, Katja; Dhanasopon, Andrew P et al. (2008) Three-dimensional electrospun ECM-based hybrid scaffolds for cardiovascular tissue engineering. Biomaterials 29:2907-14
Goodfellow, Sarah J; Innes, Fiona; Derblay, Louise E et al. (2006) Regulation of RNA polymerase III transcription during hypertrophic growth. EMBO J 25:1522-33
MacLellan, W R; Garcia, A; Oh, H et al. (2005) Overlapping roles of pocket proteins in the myocardium are unmasked by germ line deletion of p130 plus heart-specific deletion of Rb. Mol Cell Biol 25:2486-97
Ji, Aimin; Dao, Diem; Chen, Jiexiao et al. (2003) EID-2, a novel member of the EID family of p300-binding proteins inhibits transactivation by MyoD. Gene 318:35-43
Xiao, G; Mao, S; Baumgarten, G et al. (2001) Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res 89:1122-9